Canada will soon have an important new drug treatment for patients with high cholesterol, especially those with familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) whose cholesterol is not well managed on statins. The Canadian Heart Patient Alliance is submitting patient evidence to the drug review agencies and needs your feedback. The survey takes about 8 minutes to complete. Closing date: April 2, 2021.